pharma · Hypertension
Innovent Biologics
Innovent Biologics (Suzhou) Co.
NovaPharmaNews editorial coverage mentioning Innovent Biologics — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Suzhou, CN
- Founded
- 2011
- Employees
- 850
- Programs
- 2
- Drugs
- 3
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Innovent Biologics — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Innovent Biologics — regulatory, clinical, and market analysis.
Innovent Biologics Shares Surge 10% Following Pfizer Deal
Innovent Biologics' shares have surged by 10% following a major partnership with Pfizer valued at up to $10.5 billion. This article analyzes the market impact and future implications.
Innovent Biologics and Pfizer's $10.5 Billion Cancer Drug Deal
Innovent Biologics and Pfizer have entered a significant $10.5 billion deal for a cancer drug, marking a pivotal moment in China's biotech landscape. This article explores the implications for the pharmaceutical industry.
Innovent Biologics and Pfizer: A $10.5B Oncology Partnership
Innovent Biologics has signed a landmark $10.5 billion deal with Pfizer to conduct 12 cancer drug trials. This partnership is set to significantly impact the oncology market.